Wave Life Sciences Announces Singapore Court Hearing, to be held on July 14, 2026 to Approve Scheme of Arrangement for Redomiciliation

CAMBRIDGE, Mass., July 07, 2026 (GLOBE NEWSWIRE) -- As previously announced, Wave Life Sciences Ltd. (NASDAQ: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health (“ Wave ” or “ Wave Life Sciences ”), has obtained the requisite shareholder approval required in connection with its proposed redomiciliation (“ Redomiciliation ”) to the United States by way of the implementation of a statutory procedure known as a scheme of arrangement under Section 210 of the Companies Act 1967 of Singapore (the “ Scheme of Arrangement ”). The Scheme of Arrangement remains subject to approval by the High Court of the Republic of Singapore (the “ Singapore Court ”).